NEW YORK, May 25 (GenomeWeb News) - First Genetic Trust said today that it will use its enTrust genetic banking platform in a research collaboration with GlaxoSmithKline to study the relationship between genetic variations and certain adverse drug reactions.
The companies entered a similar collaboration in October 2001. FGT called the new agreement a "further research collaboration" with GSK, but did not provide details on whether the expanded effort is a renewal of the original agreement or a new project.
FGT said that GSK will use enTrust to collect, store, and manage patient enrollment, informed consent, and clinical data to support the project.
The system will also be used to re-contact patients online for additional consent for new research or phenotypic information, FGT said.